ArticleJournal of Alzheimer's disease : JAD2022
Cognitive Heterogeneity and Risk of Progression in Data-Driven Subtle Cognitive Decline Phenotypes.
Article in Journal of Alzheimer's disease : JAD, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact.Annals of clinical and translational neurology · 2026Article
- Data‑driven cognitive composites predict Aβ‑related decline and progression to MCI: the ADOPIC study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Identifying cognitive subgroups in older adults from community data with hierarchical cluster analysis.GeroScience · 2026Article
- Classifying cognitive status with TabCAT Match and UDS executive function tests.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Classification and prediction of Alzheimer's disease stages and conversion from mild cognitive impairment based on multimodal data fusion.Frontiers in aging neuroscience · 2026Article
- Neuropsychiatric symptom phenotypes for early detection of risk in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Comparing clinical features of behavioral variant frontotemporal dementia and Alzheimer's disease using network analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy.Neuro-oncology · 2025Article
- Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217.The journal of prevention of Alzheimer's disease · 2025Article
- Heterogeneity in cognitive profiles of monolingual and bilingual Hispanic/Latino older adults in HABS-HD.Journal of the International Neuropsychological Society : JINS · 2024Article
- Data-driven classification of cognitively normal and mild cognitive impairment subtypes predicts progression in the NACC dataset.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Empirically derived psychosocial-behavioral phenotypes in Black/African American and Hispanic/Latino older adults enrolled in HABS-HD: Associations with AD biomarkers and cognitive outcomes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Cognition and Amyloid-β in Older Veterans: Characterization and Longitudinal Outcomes of Data-Derived Phenotypes.Journal of Alzheimer's disease : JAD · 2024Article
- Uncovering heterogeneous cognitive trajectories in mild cognitive impairment: a data-driven approach.Alzheimer's research & therapy · 2023Article
- Data-driven neuropsychological phenotypes in the Baltimore Longitudinal Study of Aging.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThere is increasing recognition of cognitive and pathological heterogeneity in early-stage Alzheimer's disease and other dementias. Data-driven approaches have demonstrated cognitive heterogeneity in those with mild cognitive impairment (MCI), but few studies have examined this heterogeneity and its association with progression to MCI/dementia in cognitively unimpaired (CU) older adults.
objectiveWe identified cluster-derived subgroups of CU participants based on comprehensive neuropsychological data and compared baseline characteristics and rates of progression to MCI/dementia or a Dementia Rating Scale (DRS) of ≤129 across subgroups.
methodsHierarchical cluster analysis was conducted on individual baseline neuropsychological test scores from 365 CU participants in the UCSD Shiley-Marcos Alzheimer's Disease Research Center longitudinal cohort. Cox regressions examined the risk of progression to consensus diagnosis of MCI or dementia, or to DRS score ≤129, by cluster group.
resultsCluster analysis identified 5 groups: All-Average (n = 139), Low-Visuospatial (n = 46), Low-Executive (n = 51), Low-Memory/Language (n = 83), and Low-All Domains (n = 46). Subgroups had unique demographic and clinical characteristics. Rates of progression to MCI/dementia or to DRS ≤129 were faster for all subgroups (Low-All Domains progressed the fastest > Low Memory/Language≥Low-Visuospatial and Low-Executive) relative to the All-Average subgroup.
conclusionFaster progression in the Low-Visuospatial, Low-Executive, and Low-Memory/Language groups compared to the All-Average group suggests that there are multiple pathways and/or unique subtle cognitive decline profiles that ultimately lead to a diagnosis of MCI/dementia. Use of comprehensive neuropsychological test batteries that assess several domains may be a key first step toward an individualized approach to early detection and fewer missed opportunities for early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.